Millimetre continuum observations of comet C/2009 P1 (Garradd)

Little is known about the physical properties of the nuclei of Oort cloud comets. Measuring the thermal emission of a nucleus is one of the few means for deriving its size and constraining some of its thermal properties. We attempted to measure the nucleus size of the Oort cloud comet C/2009 P1 (Garradd). We used the Plateau de Bure Interferometer to measure the millimetric thermal emission of this comet at 157 GHz (1.9 mm) and 266 GHz (1.1 mm). Whereas the observations at 266 GHz were not usable due to bad atmospheric conditions, we derived a 3-sigma upper limit on the comet continuum emission of 0.41 mJy at 157 GHz. Using a thermal model for a spherical nucleus with standard thermal parameters, we found an upper limit of 5.6 km for the radius. The dust contribution to our signal is estimated to be negligible. Given the water production rates measured for this comet and our upper limit, we estimated that Garradd was very active, with an active fraction of its nucleus larger than 50%.Comment: Accepted for publication in Astronomy & Astrophysics. 5 pages, 2 figure

Optimal interactions of light with magnetic and electric resonant particles

This work studies the limits of far and near-field electromagnetic response of sub-wavelength scatterers, like the unitary limit and of lossless scatterers, and the ideal absorption limit of lossy particles. These limit behaviors are described in terms of analytic formulas that approximate finite size effects while rigorously including radiative corrections. This analysis predicts the electric and/or magnetic limit responses of both metallic and dielectric nanoparticles while quantitatively describing near-field enhancements.Comment: 9 pages, 8 figures, 2 table

Large excess of heavy nitrogen in both hydrogen cyanide and cyanogen from comet 17P/Holmes

From millimeter and optical observations of the Jupiter-family comet 17P/Holmes performed soon after its huge outburst of October 24, 2007, we derive 14 N/15N = 139 +/- 26 in HCN, and 14N/15N = 165 +/- 40 in CN, establishing that HCN has the same non-terrestrial isotopic composition as CN. The same conclusion is obtained for the long-period comet C/1995 O1 (Hale-Bopp) after a reanalysis of previously published measurements. These results are compatible with HCN being the prime parent of CN in cometary atmospheres. The 15N excess relative to the Earth atmospheric value indicates that N-bearing volatiles in the solar nebula underwent important N isotopic fractionation at some stage of Solar System formation. HCN molecules never isotopically equilibrated with the main nitrogen reservoir in the solar nebula before being incorporated in Oort-cloud and Kuiper-belt comets. The 12C/13C ratios in HCN and CN are measured to be consistent with the terrestrial value.Comment: Accepted for publication in the Astrophysical Journal (Letters) 4 page

Distributed neural system for general intelligence revealed by lesion mapping

General intelligence (g) captures the performance variance shared across cognitive tasks and correlates with real-world success. Yet it remains debated whether g reflects the combined performance of brain systems involved in these tasks or draws on specialized systems mediating their interactions. Here we investigated the neural substrates of g in 241 patients with focal brain damage using voxel-based lesion–symptom mapping. A hierarchical factor analysis across multiple cognitive tasks was used to derive a robust measure of g. Statistically significant associations were found between g and damage to a remarkably circumscribed albeit distributed network in frontal and parietal cortex, critically including white matter association tracts and frontopolar cortex. We suggest that general intelligence draws on connections between regions that integrate verbal, visuospatial, working memory, and executive processes

Anticonvulsants in the treatment of aggression in the demented elderly: an update

Complex psychopathological and behavioral symptoms, such as delusions and aggression against care providers, are often the primary cause of acute hospital admissions of elderly patients to emergency units and psychiatric departments. This issue resembles an interdisciplinary clinically highly relevant diagnostic and therapeutic challenge across many medical subjects and general practice. At least 50% of the dramatically growing number of patients with dementia exerts aggressive and agitated symptoms during the course of clinical progression, particularly at moderate clinical severity. METHODS: Commonly used rating scales for agitation and aggression are reviewed and discussed. Furthermore, we focus in this article on benefits and limitations of all available data of anticonvulsants published in this specific indication, such as valproate, carbamazepine, oxcarbazepine, lamotrigine, gabapentin and topiramate. RESULTS: To date, most positive and robust data are available for carbamazepine, however, pharmacokinetic interactions with secondary enzyme induction limit its use. Controlled data of valproate do not seem to support the use in this population. For oxcarbazepine only one controlled but negative trial is available. Positive small series and case reports have been reported for lamotrigine, gabapentin and topiramate. CONCLUSION: So far, data of anticonvulsants in demented patients with behavioral disturbances are not convincing. Controlled clinical trials using specific, valid and psychometrically sound instruments of newer anticonvulsants with a better tolerability profile are mandatory to verify whether they can contribute as treatment option in this indication

Pharmacokinetics evaluation of nimotuzumab in combination with doxorubicin and cyclophosphamide in patients with advanced breast cancer

EGFr (Epidermal growth factor receptor) overexpression has been detected in many tumors of epithelial origin, specifically in breast cancer and it is often associated with tumor growth advantages and poor prognosis. The nimotuzumab is a genetically engineered humanized MAb (monoclonal antibody) that recognizes an epitope located in the extracellular domain of human EGFr. The aim of this study was to assess the pharmacokinetics of nimotuzumab in patients with locally advanced breast cancer who are receiving neoadyuvant therapy combined with the AC chemotherapy regimen (i.e., 60 mg/m2 of Doxorubicin and 600 mg/m2 of Cyclophosphamide in 4 cycles every 21 days). A single center, non-controlled, open Phase I clinical trial, with histopathological diagnosis of locally advanced stage III breast cancer, was conducted in 12 female patients. Three patients were enrolled at each of the following fixed dose levels: 50, 100, 200 and 400 mg/week. Multiple intermittent short-term intravenous infusions of nimotuzumab were administered weekly, except on weeks 1 and 10, when blood samples were drawn for pharmacokinetic assessments. Nimotuzumab showed dose-dependent kinetics. No anti-idiotypic response against nimotuzumab was detected in blood samples of participants. There was not interaction between the administration of nimotuzumab and chemotherapy at the dose levels studied. The optimal biological doses ranging were estimated to be 200 mg/weekly to 400 mg/weekly